3,316,065 results match your criteria Oncology Research[Journal]


Electrochemotherapy in the Treatment of Breast Cancer Metastasis to the Skin and Subcutaneous Tissue - Multicenter Experience.

Oncol Res Treat 2018 Dec 12;42(1-2). Epub 2018 Dec 12.

Introduction: Breast cancer is responsible for more than 50% of cutaneous metastases. One of the treatment options is electrochemotherapy (ECT). It is an effective method of local tumor ablation through the application of electroporation. Read More

View Article
December 2018
1 Read

Stromal Cell-Derived CCL20 Promotes Tumor Progression and Osteolysis in Giant Cell Tumor of Bone.

Cell Physiol Biochem 2018 11;51(5):2472-2483. Epub 2018 Dec 11.

Spine Tumor Center, Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, China.

Background/aims: Giant cell tumor of bone (GCTB), one of the most common primary bone tumors, leads to extensive bone destruction. However, the mechanisms underlying GCTB progression remain elusive and prognostic factors and treatment targets are required. In the current study, we explored the function of the chemokine family member CCL20 in GCTB progression. Read More

View Article
December 2018
1 Read

A Novel Variant of the FZD4 Gene in a Chinese Family Causes Autosomal Dominant Familial Exudative Vitreoretinopathy.

Cell Physiol Biochem 2018 11;51(5):2445-2455. Epub 2018 Dec 11.

Key Laboratory of Epigenetics and Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, Luzhou,

Background/aims: Familial exudative vitreoretinopathy (FEVR) is a complex hereditary eye disorder characterized by incomplete development of the retinal vasculature, thereby affecting retinal angiogenesis.

Methods: In this study, a Chinese autosomal dominant FEVR pedigree was recruited. Ophthalmic examinations were performed, targeted next-generation sequencing was used to identify the causative gene, and Sanger sequencing was conducted to verify the candidate mutation. Read More

View Article
December 2018
1 Read

Expression Levels of microRNAs miR-93 and miR-200a in Pancreatic Adenocarcinoma with Special Reference to Differentiation and Relapse-Free Survival.

Oncology 2018 Dec 11:1-7. Epub 2018 Dec 11.

Department of Pathology, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.

Objectives: Protein levels of the transcription factor nuclear factor erythroid-derived 2-like 2 (Nrf2) and its inhibitor Kelch-like ECH-associated protein 1 (Keap1) have been proposed as prognostic factors in pancreatic ductal adenocarcinomas (PDACs). These cellular redox-state-regulating enzymes are targeted by several microRNAs, including miR-93 and miR-200a.

Methods: We assessed mRNA levels of Nrf2 and Keap1 and tissue expression of miR-93 and miR-200a in 51 patients with surgically treated PDAC. Read More

View Article
December 2018

Transition of cancer in populations in India.

Cancer Epidemiol 2018 Dec 8;58:111-120. Epub 2018 Dec 8.

Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India.

Background & Objectives: An assessment of transition of cancer in India during the past 30 years, according to changes in demographic and epidemiologic risk factors was undertaken.

Materials & Methods: Cancer registry data (http://www.ncdirindia. Read More

View Article
December 2018

Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor/Recipient Pairs with Improved Transplant Outcome.

Biol Blood Marrow Transplant 2018 Dec 8. Epub 2018 Dec 8.

Diagnostic Laboratories and Blood Research Institute, BloodCenter of Wisconsin, part of Versiti, Milwaukee, WI. Electronic address:

HLA matching by allele-level genotyping is largely based on genetic similarity between a few exons which encode the antigen recognition domain (ARD) of the HLA protein. Next-generation sequencing (NGS) can identify HLA genetic polymorphisms in non-ARD encoding exons, introns, and untranslated regions, but the impact of these polymorphisms on hematopoietic cell transplant (HCT) outcomes is unclear. We performed NGS-based sequencing of eleven HLA loci on a well-characterized retrospective cohort of 166 unrelated donor/recipient HCT pairs. Read More

View Article
December 2018
1 Read

Lens dose-response prediction modeling and cataract incidence in retinoblastoma patients after lens-sparing or whole-eye radiotherapy.

Int J Radiat Oncol Biol Phys 2018 Dec 8. Epub 2018 Dec 8.

Department of Radiation Oncology, Keck School of Medicine of USC and Children's Hospital Los Angeles, Los Angeles, CA. Electronic address:

Purpose: We retrospectively assessed the incidence of cataracts in retinoblastoma (Rb) patients treated with either lens-sparing (LSRT) or whole-eye radiotherapy (WERT). A secondary aim of this study was to model the dose-response risk of cataract.

Methods: We reviewed 65 retinoblastoma patients treated with radiotherapy (RT) at XXXX from 1997-2015. Read More

View Article
December 2018

Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Cancer Cell 2018 Dec;34(6):996-1011.e8

Finsen Laboratory, Rigshospitalet, DK-2200, Copenhagen, Denmark; Biotech Research & Innovation Centre (BRIC), University of Copenhagen, DK-2200, Copenhagen, Denmark; European Molecular Biology Laboratory (EMBL), Genome Biology Unit, 69120 Heidelberg, Germany; Charité Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin, Germany. Electronic address:

Identifying the earliest somatic changes in prostate cancer can give important insights into tumor evolution and aids in stratifying high- from low-risk disease. We integrated whole genome, transcriptome and methylome analysis of early-onset prostate cancers (diagnosis ≤55 years). Characterization across 292 prostate cancer genomes revealed age-related genomic alterations and a clock-like enzymatic-driven mutational process contributing to the earliest mutations in prostate cancer patients. Read More

View Article
December 2018

Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer.

Cancer Cell 2018 Dec;34(6):954-969.e4

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for Molecular Medicine and Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan. Electronic address:

Multiple mechanisms of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been identified in EGFR-mutant non-small cell lung cancer (NSCLC); however, recurrent resistance to EGFR TKIs due to the heterogeneous mechanisms underlying resistance within a single patient remains a major challenge in the clinic. Here, we report a role of nuclear protein kinase Cδ (PKCδ) as a common axis across multiple known TKI-resistance mechanisms. Specifically, we demonstrate that TKI-inactivated EGFR dimerizes with other membrane receptors implicated in TKI resistance to promote PKCδ nuclear translocation. Read More

View Article
December 2018
23.523 Impact Factor

Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling.

Cancer Cell 2018 Dec;34(6):922-938.e7

Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:

Drug resistance represents a major challenge to achieving durable responses to cancer therapeutics. Resistance mechanisms to epigenetically targeted drugs remain largely unexplored. We used bromodomain and extra-terminal domain (BET) inhibition in neuroblastoma as a prototype to model resistance to chromatin modulatory therapeutics. Read More

View Article
December 2018

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Cancer Cell 2018 Dec;34(6):893-905.e8

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA; Breast Medicine Service, Department of Medicine, MSKCC, New York, NY 10065, USA; Weill-Cornell Medical College, New York, NY 10065, USA. Electronic address:

Cyclin dependent kinase 4/6 (CDK4/6) inhibitors (CDK4/6i) are effective in breast cancer; however, drug resistance is frequently encountered and poorly understood. We conducted a genomic analysis of 348 estrogen receptor-positive (ER) breast cancers treated with CDK4/6i and identified loss-of-function mutations affecting FAT1 and RB1 linked to drug resistance. FAT1 loss led to marked elevations in CDK6, the suppression of which restored sensitivity to CDK4/6i. Read More

View Article
December 2018
1 Read

Initiation and Evolution of Early Onset Prostate Cancer.

Cancer Cell 2018 Dec;34(6):874-876

Hematology-Oncology Division, Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address:

In this issue of Cancer Cell, Gerhauser et al. analyze early-onset prostate cancers, showing roles for androgen receptor-driven rearrangements, an early APOBEC-driven mutational mechanism, and ESRP1 gene duplication. Through integration of whole-genome, transcriptome, and methylome data, they identify high-risk subgroups and develop an algorithm that may predict molecular evolution. Read More

View Article
December 2018

From Basic Knowledge to Effective Therapies.

Cancer Cell 2018 Dec;34(6):871-873

Division of Cancer Epigenomics, German Cancer Research Center, Heidelberg, Germany; The German Cancer Research Consortium. Electronic address:

In this issue of Cancer Cell, Ott et al. use integrative analysis of histone ChIP-seq and ATAC-seq to describe enhancer-based regulatory circuits in chronic lymphocytic leukemia. This work identified and validated transcription factor PAX5 as main driver of an oncogenic circuitry, which can be disrupted by BET bromodomain inhibition. Read More

View Article
December 2018

The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients.

Cancer Cell 2018 Dec;34(6):1012-1026.e3

INSERM, Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, 75006 Paris, France. Electronic address:

Treatment of metastatic colorectal cancer is based upon the assumption that metastases are homogeneous within a patient. We quantified immune cell types of 603 whole-slide metastases and primary colorectal tumors from 222 patients. Primary lesions, and synchronous and metachronous metastases, had a heterogeneous immune infiltrate and mutational diversity. Read More

View Article
December 2018
2 Reads

The microRNA miR-181c enhances chemosensitivity and reduces chemoresistance in breast cancer cells via down-regulating osteopontin.

Int J Biol Macromol 2018 Dec 8. Epub 2018 Dec 8.

Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.

Acquired resistance to chemotherapy is a frequent challenge in cancer care and one of the leading causes for failing breast cancer therapies. There is accumulative clinical and experimental evidence indicating that microRNAs (miRNAs) play a crucial role in developing therapeutic resistance in cancer cells. We aimed to explore key miRNAs and associated mechanisms by which breast cancer develops chemoresistance. Read More

View Article
December 2018
1 Read

Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting Clinicopathologic features of upper urinary tract urothelial carcinoma.

Hum Pathol 2018 Dec 8. Epub 2018 Dec 8.

Department of Pathology, University of Michigan, 2800 Plymouth Road, Building 35, Ann Arbor, MI 48109, USA; Michigan Center for Translational Pathology, 5309 CCC 5940, 1500 E. Medical Center Drive, Ann Arbor, MI, 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, 1500 E Medical Center Drive, Ann Arbor, MI, 48109, USA. Electronic address:

5% of urothelial carcinoma occurs in the upper urinary tract (UUT), a challenging location to biopsy. We aim to evaluate concordance between biopsy, cytology, and resection specimens in a large upper tract urothelial carcinoma (UTUC) cohort.117 UTUC resections with UUT biopsy and/or cytology specimens from 2000-2016 were retrieved; pathologic material was re-reviewed, evaluated for concordance, and correlated with clinical information. Read More

View Article
December 2018

Molecular characterization of metaplastic breast carcinoma via next generation sequencing.

Hum Pathol 2018 Dec 8. Epub 2018 Dec 8.

Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte 91010, USA.

Metaplastic breast carcinoma (MBC) is a rare subtype of breast cancer with variable morphology. MBC is more often triple negative (ER-, PR-, HER2-) and is associated with poorer clinical outcome when compared to infiltrating ductal carcinoma. The purpose of our study is to identify molecular alterations in MBC using next generation sequencing (NGS) which may aid chemotherapy selection and use of targeted therapy. Read More

View Article
December 2018

Thymic epithelial neoplasms with sebaceous differentiation: a clinicopathological and Immunohistochemical study of 8 cases.

Hum Pathol 2018 Dec 8. Epub 2018 Dec 8.

Department of Pathology, The university of Texas, M D Anderson Cancer Center, Houston, TX. Electronic address:

Eight cases of primary thymic epithelial neoplasms corresponding to seven thymomas and one thymic carcinoma with sebaceous differentiation are presented. The patients are five men and three women between the ages of 45 and 63years (average: 54years) who presented with non-specific symptomatology related to their mediastinal mass. All patients underwent complete surgical resection of the mediastinal mass. Read More

View Article
December 2018

Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes.

J Control Release 2018 Dec 8. Epub 2018 Dec 8.

Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 1-5, 8093 Zurich, Switzerland.

In glioblastoma, the benefit from temozolomide chemotherapy is largely limited to a subgroup of patients (30-35%) with tumors exhibiting methylation of the promoter region of the O-methylguanine-DNA methyltransferase (MGMT) gene. In order to allow more patients to benefit from this treatment, we explored magnetic resonance image-guided microbubble-enhanced low-intensity pulsed focused ultrasound (LIFU) to transiently open the blood-brain barrier and deliver a first-in-class liposome-loaded small molecule MGMT inactivator in mice bearing temozolomide-resistant gliomas. We demonstrate that a liposomal O-(4-bromothenyl)guanine (OBTG) derivative can efficiently target MGMT, thereby sensitizing murine and human glioma cells to temozolomide in vitro. Read More

View Article
December 2018

GNAQ Mutations in Diffuse and Solitary Choroidal Hemangiomas.

Ophthalmology 2018 Dec 8. Epub 2018 Dec 8.

Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical Center, New York, NY.

Purpose: GNAQ mutations have been identified in port wine stains (both syndromic and non-syndromic) and melanocytic ocular neoplasms. This study investigates the presence of GNAQ mutations in diffuse- (those associated with Sturge-Weber syndrome (SWS)) and solitary choroidal hemangiomas.

Participants: Tissue from 11 patients with the following diagnoses: port wine stain (n = 3), diffuse choroidal hemangioma (n = 1), solitary choroidal hemangioma (n = 6), choroidal nevus (n =1) METHODS: Ten specimens were interrogated with Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), a hybridization capture-based next-generation sequencing assay for targeted deep sequencing of all exons and selected introns of 468 key cancer genes in formalin-fixed, paraffin-embedded tumors. Read More

View Article
December 2018
1 Read

Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction.

J Oncol Pract 2018 Dec;14(12):e823-e833

Yale New Haven Hospital; Yale School of Medicine; Yale Cancer Center; Smilow Cancer Hospital; and Community Health Educators Group, New Haven, CT.

Purpose:: Many US academic centers have acquired community practices to expand their clinical care and research footprint. The objective of this assessment was to determine whether the acquisition and integration of community oncology practices by Yale/Smilow Cancer Hospital improved outcomes in quality of care, disease team integration, clinical trial accrual, and patient satisfaction at network practice sites.

Methods:: We evaluated quality of care by testing the hypothesis that core Quality Oncology Practice Initiative measures at network sites that were acquired in 2012 were significantly different after their 2016 integration into the network. Read More

View Article
December 2018
1 Read

Benefits and Challenges of Growing Oncology Networks in the United States.

J Oncol Pract 2018 Dec;14(12):761-762

City of Hope Medical Group, Duarte, CA.

View Article
December 2018

Impact of Closed Facebook Group Participation on Female Hematology/Oncology Physicians.

J Oncol Pract 2018 Dec;14(12):e758-e769

Sarah Cannon Cancer Institutes at HCA Midwest Health, Overland Park, KS; University of Florida College of Medicine; Malcom Randall Veterans Affairs Medical Center, Gainesville; Florida Cancer Specialists, Deland, FL; University of Texas Southwestern Medical Center, Dallas, TX; and Cleveland Clinic Akron General, Akron, OH.

Purpose:: Meaningful connections are an important aspect of career satisfaction. The Hematology Oncology Women Physician Group (HOWPG) is a private Facebook (FB) group of 936 women who practice within the hematology/oncology (H/O) field. We hypothesized that HOWPG adds value to education, emotional wellness, and practice of oncology for its membership. Read More

View Article
December 2018
1 Read

Real-World Approaches to Quality Improvement in Oncology.

J Oncol Pract 2018 Dec;14(12):757-759

Duke Cancer Institute, Durham, NC; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

View Article
December 2018

1-2-3 Project: A Quality Improvement Initiative to Normalize and Systematize Palliative Care for All Patients With Cancer in the Outpatient Clinic Setting.

J Oncol Pract 2018 Dec;14(12):e775-e785

Memorial Sloan Kettering Cancer Center, New York, NY.

Background:: Prior work to integrate early palliative care in oncology has focused on patients with advanced cancer and primarily on palliative care consultation. We developed this outpatient clinic initiative for newly diagnosed patients at any stage, emphasizing primary (nonspecialist) palliative care by oncology teams, with enhanced access to palliative care specialists.

Methods:: We piloted the project in two medical oncology specialty clinics (for patients with myelodysplastic syndrome and GI cancer, respectively) to establish feasibility. Read More

View Article
December 2018

Quality Improvement Training in a Variety of Cancer Care Delivery Settings: Experiences From a Comprehensive Cancer Center, an Academic Medical Center, and Community Practices.

J Oncol Pract 2018 Dec;14(12):e815-e822

Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Partners HealthCare; and Massachusetts General Hospital, Boston, MA.

Purpose:: Training clinical and supportive staff in quality improvement (QI) theory and use of QI tools has the potential to improve oncology care delivery. We report our combined experience of providing training to oncologists in a variety of local settings and assess the effect of the training on individual participants and for institutions.

Methods:: Multidisciplinary oncology teams at a comprehensive cancer center, an academic medical center, and community practices were led through experiential QI training that spanned several months. Read More

View Article
December 2018

Comparison of Quality Oncology Practice Initiative Metrics in Solid Tumor Oncology Clinic With or Without Concomitant Supportive Oncology Consultation.

J Oncol Pract 2018 Dec;14(12):e786-e793

Icahn School of Medicine at Mount Sinai, New York, NY; and The Everett Clinic, Providence Regional Medical Center, Everett, WA.

Purpose:: The Quality Oncology Practice Initiative (QOPI) is a quality measurement and improvement program designed to assess practice performance for various consensus-based and evidence-based measures. In this study, we evaluated differences in QOPI metrics met among patients with advanced solid cancer receiving routine oncologic care alone (routine care) compared with patients receiving integrated oncology and specialty-level palliative care (supportive care).

Methods:: We conducted a retrospective chart review of 100 randomly selected patients treated between June 2013 and June 2015 from our supportive care group and matched these patients to 100 routine care group patients on the basis of tumor type and initial oncology visit date. Read More

View Article
December 2018

Lessons From Reporting National Performance Measures in a Regional Setting: Washington State Community Cancer Care Report.

J Oncol Pract 2018 Dec;14(12):e801-e814

Fred Hutchinson Cancer Research Center, Seattle, WA; Premera Blue Cross, Mountlake Terrace, WA; and University of Washington School of Medicine, Seattle, WA.

Regional public reporting of performance measures in oncology can facilitate local decision making across stakeholders, but small numbers of patients and clinics pose a challenge to creating statistically robust measures. In this article, we describe our development of the Community Cancer Care in Washington State: Quality and Cost Report, the first publicly available report showing clinic-level quality and cost measures at the regional level. We learned key lessons in how to adapt national performance reporting to our regional setting using a registry-linked multipayer claims database. Read More

View Article
December 2018
1 Read

The value of immunotherapy in head and neck cancer.

Expert Opin Biol Ther 2018 Dec 11. Epub 2018 Dec 11.

d Marlene and Stewart Greenebaum Comprehensive Cancer Center , University of Maryland School of Medicine , Baltimore , Maryland.

Introduction: Head and neck squamous cell carcinomas (HNSCC) previously had limited treatment options once patients had progressed on systemic chemotherapy. With recent advances, immunotherapy now plays an important role in the treatment of advanced disease with improved outcomes as compared to cytotoxic chemotherapy. Areas covered: This article reviews the effects of the immune system and how it influences the development and response to HNSCC therapy. Read More

View Article
December 2018
1 Read

Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature.

Pediatr Blood Cancer 2018 Dec 10:e27569. Epub 2018 Dec 10.

Department of Pediatrics, Hematology/Oncology Section, Baylor College of Medicine, Houston, Texas.

Autoimmune cytopenias (AIC) post-hematopoietic stem cell transplant (HSCT) are rare but exceptionally challenging complication. We conducted a comprehensive literature review and identified a pooled incidence of post-HSCT autoimmune hemolytic anemia and/or immune thrombocytopenia of 2.66% (SE = 0. Read More

View Article
December 2018

Prognostic value of metabolic tumor burden calculated using dual-time-point 18F-fluorodeoxyglucose positron emission tomography/CT in patients with oropharyngeal or hypopharyngeal cancer.

Head Neck 2018 Dec 10. Epub 2018 Dec 10.

Department of Radiation Therapeutics and Oncology, Tokyo Medical and Dental University, Tokyo, Japan.

Background: This study investigates the prognostic value of metabolic tumor burden calculated using dual-time-point 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)/CT in patients with locally advanced cancer.

Methods: This study examines 42 patients (35 men and 7 women, 38-73 years old) with locally advanced oropharyngeal or hypopharyngeal cancer who had undergone FDG-PET/CT before receiving chemoradiotherapy. Maximum standardized uptake value (SUV ), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured for the early and delayed phases. Read More

View Article
December 2018

Depth of invasion as a predictor of nodal disease and survival in patients with oral tongue squamous cell carcinoma.

Head Neck 2018 Dec 7. Epub 2018 Dec 7.

Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: Depth of invasion (DOI) in oral cavity cancer is important in determining prognosis. This study aims to determine optimal cut-points of DOI for detection of occult disease and survival.

Methods: A retrospective cohort study was completed of previously untreated early stage lateral oral tongue cancer. Read More

View Article
December 2018

Bioinformatic analysis of the prognostic value of the lncRNAs encoding snoRNAs in hepatocellular carcinoma.

Biofactors 2018 Dec 8. Epub 2018 Dec 8.

Department of Oncology Radiotherapy, Henan Provincial People's Hospital, Zhengzhou, Henan, China.

Some lncRNAs can encode small nucleolar RNAs (snoRNAs), called small nucleolar RNA host genes (SNHGs), which exert diverse regulatory effects on cellular processes. In this study, using RNA-seq and survival data in the Cancer Genome Atlas (TCGA)-Liver Hepatocellular Carcinoma (LIHC), we examined the expression profile of some SNHG genes and explored their prognostic value in hepatocellular carcinoma (HCC). Level-3 RNA-sequencing data, the clinicopathological and survival data of patients with primary HCC were downloaded from the UCSC Xena browser (https://xenabrowser. Read More

View Article
December 2018
2 Reads

Long-Term Consequences of the Chernobyl Radioactive Fallout: An Exploration of the Aggregate Data.

Milbank Q 2018 Dec;96(4):814-857

University of Padua.

Policy Points Policymakers should invest more on researching the long-term health effects of low-ionizing radiation exposure, as we are far from reaching a consensus on a topic that is of enormous importance for public health and safety. Public policies such as those limiting the import of contaminated food from areas hit by a radioactive disaster or those regulating the resident population's access to such areas should follow a precautionary approach. Neoplasm diagnosis and medical care should be designed in order to take into account the possible role of long-term, low-dose radiation exposure. Read More

View Article
December 2018
2 Reads

Disparities in Breast Cancer Survival by Socioeconomic Status Despite Medicare and Medicaid Insurance.

Milbank Q 2018 Dec;96(4):706-754

Leonard and Madlyn Abramson Cancer Center of the University of Pennsylvania.

Policy Points Patients with low socioeconomic status (SES) experience poorer survival rates after diagnosis of breast cancer, even when enrolled in Medicare and Medicaid. Most of the difference in survival is due to more advanced cancer on presentation and the general poor health of lower SES patients, while only a very small fraction of the SES disparity is due to differences in cancer treatment. Even when comparing only low- versus not-low-SES whites (without confounding by race) the survival disparity between disparate white SES populations is very large and is associated with lower use of preventive care, despite having insurance. Read More

View Article
December 2018

Melatonin inhibits the migration of human gastric carcinoma cells at least in part by remodeling tight junction.

J Cell Biochem 2018 Dec 9. Epub 2018 Dec 9.

Laboratory of Molecular Biology and Department of Biochemistry, Anhui Medical University, Hefei, People's Republic of China.

The recurrence and metastasis is one of the major reasons for malignant tumor treatment failure. Melatonin, a naturally occuring hormone, could reduce the recurrence and metastasis of various tumors. However, the underlying molecular mechanisms of melatonin on tumor metastasis inhibition have not been fully elucidated. Read More

View Article
December 2018

Proton therapy for skull base tumors: A review of clinical outcomes for chordomas and chondrosarcomas.

Head Neck 2018 Dec 7. Epub 2018 Dec 7.

University of Florida Health Proton Therapy Institute, University of Florida College of Medicine, Jacksonville, Florida.

Background: Skull base chordomas and chondrosarcomas are rare tumors traditionally treated by surgical resection and adjuvant radiation therapy (RT). We will discuss data evaluating clinical outcomes of proton therapy in the treatment of skull base chordomas and chondrosarcomas.

Methods: A literature review was performed using a MEDLINE search from January 1990 to January 2017. Read More

View Article
December 2018

Delphinidin inhibits epidermal growth factor-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma cells.

J Cell Biochem 2018 Dec 9. Epub 2018 Dec 9.

Laboratory of Molecular Oncology, Cheil General Hospital & Women's Healthcare Center, College of Medicine, Dankook University, Seoul, South Korea.

Epithelial-to-mesenchymal transition (EMT), important cellular process in metastasis of primary tumors, is characterized by loss of their cell polarity, disruption of cell-cell adhesion, and gain certain properties of mesenchymal phenotype that enable migration and invasion. Delphinidin is a member of anthocyanidin belong to flavonoid groups, known as having pharmacological and physiological effects including anti-tumorigenic, antioxidative, anti-inflammatory, and antiangiogenic effects. However, the effects of delphinidin on EMT is rarely investigated. Read More

View Article
December 2018

Treating tumors at low drug doses using an aptamer-peptide synergistic drug conjugate.

Angew Chem Int Ed Engl 2018 Dec 11. Epub 2018 Dec 11.

Harvard University John A Paulson School of Engineering and Applied Sciences, 29 Oxford Street, 02138, Cambridge, UNITED STATES.

Combination chemotherapy must strike a difficult balance between safety and efficacy. Current regimens suffer from poor therapeutic impact because drugs are given at their maximum tolerated dose (MTD), which compounds the toxicity risk and exposes tumors to non-optimal drug ratios. We developed a modular framework that selectively delivers drug combinations at synergistic ratios via tumor-targeting aptamers for effective low-dose treatment. Read More

View Article
December 2018

An in vitro assessment for evaluating the efficiency of β-d-mannuronic acid (M2000) in myelodysplastic syndrome.

J Cell Physiol 2018 Dec 10. Epub 2018 Dec 10.

Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

β-d-Mannuronic acid (M2000), a novel non-steroidal anti-inflammatory drug (NSAID) with immunosuppressive properties, has been previously shown to exhibit potential therapeutic effects on autoimmune diseases. Immunosuppression therapy has been a standard approach for myelodysplastic syndrome (MDS) for many years. We evaluated the effect of M2000 on isolated peripheral blood mononuclear cells (PBMCs) from patients with MDS. Read More

View Article
December 2018

Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy.

Prostate 2018 Dec 9. Epub 2018 Dec 9.

Urological Research Centre, Department of Urology, Vejle Hospital, Vejle, Denmark.

Background: Overtreatment is a well-known clinical challenge in local prostate cancer (PCa). Although risk assessment models have contributed to a better stratification of patients with local PCa, a tailored management is still in its infancy. Over the last few decades, microRNAs (miRNAs) have shown promising results as biomarkers in PCa. Read More

View Article
December 2018

Technical Note: A method for quality assurance of landmark sets for use in evaluation of deformable image registration accuracy of lung parenchyma.

Med Phys 2018 Dec 11. Epub 2018 Dec 11.

Department of Radiation Oncology, Washington University in St. Louis, St. Louis, MO, 63110, USA.

Purpose: To develop a quality control method to improve the accuracy of corresponding landmark sets used for deformable image registration evaluation in the lung parenchyma.

Methods: An iterative workflow was developed as a method for quality assurance of landmark sets. Starting with the initial landmark set for a given image pair, a landmark-based deformation was applied to one of the images. Read More

View Article
December 2018

Anti-oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient-derived tumor xenograft model.

Head Neck 2018 Dec 10. Epub 2018 Dec 10.

School of Dentistry, National Defense Medical Center, Taipei, Taiwan.

Background: Aberrant expression of decoy receptor 3 (DcR3) is considered to be a diagnostic and therapeutic target for human cancers. The aim of this study was to assess DcR3 as a target of the anticancer effects of triptolide (TPL) in preclinical patient-derived tumor xenograft (PDTX) models of oral squamous cell carcinoma (OSCC).

Methods: The expression of DcR3 was evaluated through immunohistochemistry, and correlations were examined using clinical variables. Read More

View Article
December 2018

Role of miR-486-5p in regulating renal cell carcinoma cell proliferation and apoptosis via TGF-β-activated kinase 1.

J Cell Biochem 2018 Dec 9. Epub 2018 Dec 9.

The Department of Oncology, Hebei Chest Hospital, Shijiazhuang, Hebei, China.

Renal cell carcinoma (RCC) is a common kidney tumor in adults. The role of miR-486-5p in RCC is unknown. The aim of our study was to identify new targets regulated by miR-486-5p in RCC, to obtain a deeper insight into the network and to better understand the role of these microRNAs and their targets in carcinogenesis of RCC. Read More

View Article
December 2018

Genetic polymorphism of rs9564966 G > A on 13q22.1 predicts poor survival for Chinese patients with gastric cancer.

Cancer Med 2018 Dec 8. Epub 2018 Dec 8.

Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Two genomewide association studies on pancreatic cancer have identified a novel single-nucleotide polymorphism of rs9564966 G > A on 13q22.1 region. However, the associations between the rs9564966 G > A polymorphism and the survival of Chinese patients with gastric cancer (GC) were unknown. Read More

View Article
December 2018

Long noncoding RNA CASC9 promotes LIN7A expression via miR-758-3p to facilitate the malignancy of ovarian cancer.

J Cell Physiol 2018 Dec 7. Epub 2018 Dec 7.

Department of Head and Neck and Genito-Urinary Oncology, Harbin Medical University Cancer Hospital, Harbin, China.

The long noncoding RNA cancer susceptibility 9 (CASC9) has been reported to be a pivot modulator in growth and metastasis of breast cancer, liver cancer, esophageal squamous cell carcinoma, lung adenocarcinoma, gastric cancer, and nasopharyngeal cancer. However, its potential roles in ovarian cancer remain unclear. In this study, we aimed at its functions and molecular mechanism in ovarian cancer progression. Read More

View Article
December 2018

Effects of GST variants on the risk odds of hematological malignancy: A meta-analysis.

J Cell Biochem 2018 Dec 9. Epub 2018 Dec 9.

Department of Medical Oncology, Linyi Cancer Hospital, Linyi, Shandong, China.

Background: Whether glutathione S-transferases (GST) polymorphisms influence the risk odds of hematological malignancy remains controversial. Therefore, we performed this meta-analysis to better analyze correlations between GST polymorphisms and hematological malignancy.

Methods: Literature retrieve was conducted in PubMed, MEDLINE, and Embase. Read More

View Article
December 2018

Are we meeting the training needs of healthcare and education professionals supporting children with cancer in their return to school?

Pediatr Blood Cancer 2018 Dec 10:e27575. Epub 2018 Dec 10.

Discipline of Paediatrics, School of Women's and Children's Health, Faculty of Medicine, UNSW Sydney, New South Wales, Australia.

View Article
December 2018

MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL.

Br J Haematol 2018 Dec 9. Epub 2018 Dec 9.

Department of Medical Oncology, Dana-Farber Cancer Institute, Cambridge, MA, USA.

The L265P somatic mutation in the Myeloid Differentiation Primary Response 88 (MYD88) gene is a recurrent mutation in chronic lymphocytic leukaemia (CLL). This mutation has functional effects in various haematological malignancies but its role in CLL remains to be fully elucidated. Here, we report that MYD88 L265P mutations are associated with mutated immunoglobulin heavy-chain gene (IGHV-M) status and that among IGHV-M patients, the presence of MYD88 L265P is associated with younger age at diagnosis. Read More

View Article
December 2018

A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer.

Pediatr Blood Cancer 2018 Dec 11:e27568. Epub 2018 Dec 11.

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.

Background: Bacillus species are known to cause severe infection in immunocompromised hosts. The incidence of Bacillus bloodstream infections and characteristics of infection among children with cancer or indication for hematopoietic cell transplant (HCT) is unknown.

Methods: We performed a retrospective medical record review of all cases of Bacillus bacteremia between January 1, 2005, and December 31, 2014, at Boston Children's Hospital. Read More

View Article
December 2018
  • Page 1 of 66322